Press Room

WASHINGTON, DC— 21 de marzo de 2024 — Hoy, el Congreso publicó una serie de proyectos de ley de asignaciones presupuestarias destinadas a finalizar el financiamiento del año fiscal 2024 que incluye un aumento de $300 millones en el financiamiento para el presupuesto base del Instituto Nacional de Salud (NIH, siglas en inglés), incluido un aumento de $120 millones en fondos discrecionales para el Instituto Nacional del Cáncer (NCI), un modesto aumento de $500,000 para los programas de detección y prevención del cáncer de los Centros para el Control y la Prevención de Enfermedades (CDC, siglas en inglés) y mantiene el nivel de financiamiento actual para la Agencia de Proyectos de Investigación Avanzada para la Salud (ARPA-H, siglas en inglés) en $1.5 mil millones.

Today, the American Cancer Society Cancer Action Network submitted a statement for the record to the House Energy & Commerce Committee Health Subcommittee in regards to their hearing on Evaluating Approaches to Diagnostic Test Regulation and the impact of the FDA’s proposed rule.

As one of the leading patient advocacy groups that advocated for the passage of the Affordable Care Act (ACA), the American Cancer Society Cancer Action Network (ACS CAN) is celebrating the impact of the historic law ahead of its 14th anniversary on Saturday. ACS CAN is marking the milestone by urging Congress, state lawmakers and the U.S. Court of Appeals for the Fifth Circuit to protect and strengthen the critical patient protections of the ACA.

The House Energy and Commerce Committee’s Subcommittee on Health today marked up the Screening for Communities to Receive Early and Equitable Needed Services (SCREENS) for Cancer Act, H.R. 3916. The bipartisan legislation would reauthorize the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) through 2028.

The American Cancer Society Cancer Action Network (ACS CAN) is pleased to see President Biden’s continued focus on and dedication to achieving the goal of the Cancer Moonshot to end cancer as we know it, for everyone.

The Biden Cancer Moonshot announced today the expansion of coverage for patient navigation services in plans from seven health insurance companies.

WASHINGTON, DC — 7 de marzo de 2024 — Antes del discurso del presidente Biden sobre el Estado de la Nación, la Red de Acción Contra el Cáncer de la Sociedad Americana Contra el Cáncer (ACS CAN, por sus siglas en inglés) insta al presidente a enfatizar la necesidad de un continuo apoyo bipartidista para aumentar la inversión federal para la investigación del cáncer en los Institutos Nacionales de la Salud (NIH, por sus siglas en inglés) y el Instituto Nacional del Cáncer (NCI, por sus siglas en inglés), así como el financiamiento de programas de prevención en los Centros para el Control y la Prevención de Enfermedades (CDC, por sus siglas en inglés). Además, ACS CAN insta al presidente a finalizar sin demora la normativa de la Administración de Alimentos y Medicamentos (FDA, por sus siglas en inglés) que prohíbe la venta de mentol en los cigarrillos.

Milwaukee attorney Philip R. O’Brien has accepted the role of Cancer Votes National Ambassador for the American Cancer Society Cancer Action Network (ACS CAN), the advocacy affiliate of the American Cancer Society (ACS). This role is an expansion of O’Brien’s current commitment to ACS CAN as a member of its national Board of Directors since 2019. Cancer Votes is ACS CAN’s nonpartisan electoral program, a public education avenue through which cancer issues are elevated as a key priority during election cycles. As National Ambassador, Phil O’Brien will serve as a brand leader, seeking to draw high levels of engagement from volunteers, the media and the advocacy and business communities.

Today, the U.S. Court of Appeals for the Fifth Circuit will hear oral arguments in Braidwood Management v. Becerra, a case that threatens access to evidence-based preventive services without cost-sharing as required under the Affordable Care Act (ACA). The services at-risk include those recommended by scientific experts at the U.S. Preventive Services Task Force (USPSTF), the Advisory Committee on Immunization Practices (ACIP) and the Health Resources and Services Administration (HRSA). 

A new paper released today in the Journal of Clinical Oncology finds that while incorporating pharmacogenomic (PGx) testing into cancer care can help improve patient outcomes, barriers to PGx testing, discovery, and implementation are impacting its adoption and creating disparities that impact diverse populations.